## Dulcinéia Saes Parra Abdalla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2207014/publications.pdf

Version: 2024-02-01

43 papers 1,324 citations

304743 22 h-index 36 g-index

45 all docs

45 docs citations

45 times ranked

1987 citing authors

#	Article	IF	CITATIONS
1	Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis, 1995, 117, 61-71.	0.8	164
2	Electronegative low-density lipoprotein: Origin and impact on health and disease. Atherosclerosis, 2011, 215, 257-265.	0.8	79
3	Lipid Peroxidation Is Associated with the Severity of Periodontal Disease and Local Inflammatory Markers in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1353-E1362.	3.6	76
4	Anti-atherogenic and anti-angiogenic activities of polyphenols from propolis. Journal of Nutritional Biochemistry, 2012, 23, 557-566.	4.2	70
5	Cholesterol oxides as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2007, 23, 35-42.	4.0	66
6	Low density lipoprotein oxidation by stimulated neutrophils and ferritin. Atherosclerosis, 1992, 97, 149-159.	0.8	65
7	High-performance liquid chromatography of fatty acids in biological samples. Analytica Chimica Acta, 2002, 465, 81-91.	5.4	60
8	Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clinical Biochemistry, 2008, 41, 1454-1460.	1.9	58
9	Coulometric detection in high-performance liquid chromatographic analysis of cholesteryl ester hydroperoxides. Free Radical Biology and Medicine, 1996, 20, 365-371.	2.9	47
10	Identification of microRNAs involved in the modulation of pro-angiogenic factors in atherosclerosis by a polyphenol-rich extract from propolis. Archives of Biochemistry and Biophysics, 2014, 557, 28-35.	3.0	43
11	Nitrotyrosine Bound to $\hat{I}^2$ -VLDL-Apoproteins: A Biomarker of Peroxynitrite Formation in Experimental Atherosclerosis. Biochemical and Biophysical Research Communications, 1997, 232, 332-335.	2.1	41
12	Lipid peroxidation and antioxidants in hyperlipidemia and hypertension. Biological Research, 2000, 33, 105-12.	3.4	41
13	Is ceruloplasmin an important catalyst for S-nitrosothiol generation in hypercholesterolemia?. Free Radical Biology and Medicine, 2001, 30, 318-326.	2.9	36
14	Effects of Simvastatin and I -arginine on Vasodilation, Nitric Oxide Metabolites and Endogenous NOS Inhibitors in Hypercholesterolemic Subjects. Free Radical Research, 2003, 37, 529-536.	3.3	34
15	Soy isoflavones reduce electronegative low-density lipoprotein (LDLâ^') and anti-LDLâ^' autoantibodies in experimental atherosclerosis. European Journal of Nutrition, 2007, 46, 125-132.	3.9	34
16	Validation of a novel ELISA for measurement of electronegative low-density lipoprotein. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1769-75.	2.3	34
17	Influence of daily consumption of synbiotic soy-based product supplemented with okara soybean by-product on risk factors for cardiovascular diseases. Food Research International, 2015, 73, 142-148.	6.2	34
18	Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects. Atherosclerosis, 2004, 177, 89-96.	0.8	31

#	Article	IF	CITATIONS
19	Identification of mildly oxidized low-density lipoprotein (electronegative LDL) and its auto-antibodies IgG in children and adolescents hypercholesterolemic offsprings. Atherosclerosis, 2006, 184, 103-107.	0.8	28
20	Alpha-tocopherol supplementation decreases electronegative low-density lipoprotein concentration [LDL(-)] in haemodialysis patients. Nephrology Dialysis Transplantation, 2009, 24, 1587-1592.	0.7	26
21	New PPAR $\hat{I}^3$ partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLr $\hat{I}^3$ mice. Pharmacological Research, 2016, 104, 49-60.	7.1	26
22	Reduced Plasma Zinc Levels, Lipid Peroxidation, and Inflammation Biomarkers Levels in Hemodialysis Patients: Implications to Cardiovascular Mortality. Renal Failure, 2013, 35, 680-685.	2.1	25
23	The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis. Journal of Trace Elements in Medicine and Biology, 2014, 28, 194-199.	3.0	22
24	Development of immunoassays for anti-electronegative LDL autoantibodies and immune complexes. Clinica Chimica Acta, 2012, 413, 291-297.	1.1	19
25	Lipid and acute-phase protein alterations in HIV-1 infected patients in the early stages of infection: correlation with CD4+ lymphocytes. Brazilian Journal of Infectious Diseases, 2001, 5, 192-9.	0.6	18
26	Effect of N-acetyl-L-cysteine on lymphocyte apoptosis, lymphocyte viability, TNF-alpha and IL-8 in HIV-infected patients undergoing anti-retroviral treatment. Brazilian Journal of Infectious Diseases, 2004, 8, 363-71.	0.6	17
27	Cloning and expression of an anti-LDL(-) single-chain variable fragment, and its inhibitory effect on experimental atherosclerosis. MAbs, 2013, 5, 763-775.	5.2	17
28	Electronegative Lowâ€Density Lipoprotein is Associated with Dense Lowâ€Density Lipoprotein in Subjects with Different Levels of Cardiovascular Risk. Lipids, 2010, 45, 619-625.	1.7	16
29	Casein and Soy Protein Isolate in Experimental Atherosclerosis: Influence on Hyperlipidemia and Lipoprotein Oxidation. Annals of Nutrition and Metabolism, 2001, 45, 38-46.	1.9	14
30	Human macrophage metabolism of low density lipoprotein oxidized by stimulated neutrophils and ferritin. Atherosclerosis, 1994, 107, 157-163.	0.8	13
31	A nanoformulation containing a scFv reactive to electronegative LDL inhibits atherosclerosis in LDL receptor knockout mice. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 107, 120-129.	4.3	12
32	Increased electronegative LDL and decreased antibodies against electronegative LDL levels correlate with inflammatory markers and adhesion molecules in hemodialysed patients. Clinica Chimica Acta, 2011, 412, 1788-1792.	1.1	10
33	The Hypolipidemic and Pleiotropic Effects of Rosuvastatin Are Not Enhanced by Its Association with Zinc and Selenium Supplementation in Coronary Artery Disease Patients: A Double Blind Randomized Controlled Study. PLoS ONE, 2015, 10, e0119830.	2.5	10
34	Peroxidação lipÃdica em pacientes com insuficiência renal crônica. Revista De Nutricao, 1999, 12, 205-212.	0.4	10
35	Role of electronegative LDL and its associated antibodies in the pathogenesis of atherosclerosis. Clinical Lipidology, 2010, 5, 719-729.	0.4	7
36	Proinflammatory Action of a New Electronegative Low-Density Lipoprotein Epitope. Biomolecules, 2019, 9, 386.	4.0	7

#	Article	IF	Citations
37	Biomarcadores de peroxidação lipÃdica na aterosclerose. Revista De Nutricao, 2008, 21, 749-756.	0.4	5
38	Predictive Potential of Twenty-Two Biochemical Biomarkers for Coronary Artery Disease in Type 2 Diabetes Mellitus. International Journal of Endocrinology, 2015, 2015, 1-8.	1.5	4
39	GFPâ€SCFV: Expression and possible applications as a tool for experimental investigations of atherosclerosis. Biotechnology Progress, 2014, 30, 1206-1213.	2.6	3
40	Inflammasome Activation in Human Macrophages Induced by a LDL (â^') Mimetic Peptide. Inflammation, 2020, 43, 722-730.	3.8	2
41	Patologia. BJPS: Brazilian Journal of Pharmaceutical Sciences, 2002, 38, 373-374.	0.5	O
42	Nutrição e doenças cardiovasculares: prevenção primária e secundária. BJPS: Brazilian Journal of Pharmaceutical Sciences, 2004, 40, 559-560.	0.5	0
43	Molecular mechanisms of atherosclerosis. BJPS: Brazilian Journal of Pharmaceutical Sciences, 2006, 42, 617-618.	0.5	0